It has been suggested that APR-246 may exert its best efficacy in cell lines that have TP53 mutations primarily in exons 5–8 (where the majority are located) such as in breast cancer or in cancers where it has a non-functional conformation [80,81]. Here, TP53 is linked to breast cancer.